Archivio istituzionale della ricerca dell'Università degli Studi di Palermo

GALVANO, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 10.600
EU - Europa 4.666
AS - Asia 3.948
SA - Sud America 729
Continente sconosciuto - Info sul continente non disponibili 721
AF - Africa 143
OC - Oceania 18
Totale 20.825
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 10.309
SG - Singapore 1.569
RU - Federazione Russa 1.411
IT - Italia 1.211
CN - Cina 856
BR - Brasile 574
DE - Germania 487
VN - Vietnam 417
HK - Hong Kong 355
FI - Finlandia 298
PL - Polonia 270
GB - Regno Unito 251
FR - Francia 224
CA - Canada 153
JP - Giappone 152
BD - Bangladesh 107
IN - India 107
IE - Irlanda 90
SE - Svezia 88
KR - Corea 77
NL - Olanda 77
MX - Messico 54
IQ - Iraq 53
AR - Argentina 45
TR - Turchia 45
RO - Romania 44
ES - Italia 42
UA - Ucraina 37
ZA - Sudafrica 34
AT - Austria 28
VE - Venezuela 28
BE - Belgio 26
MY - Malesia 25
EC - Ecuador 24
UZ - Uzbekistan 23
IR - Iran 21
EG - Egitto 20
ID - Indonesia 20
JM - Giamaica 20
MA - Marocco 18
AU - Australia 17
KE - Kenya 17
CI - Costa d'Avorio 16
CO - Colombia 16
SA - Arabia Saudita 16
CH - Svizzera 14
PK - Pakistan 14
CL - Cile 12
CR - Costa Rica 12
NP - Nepal 12
PH - Filippine 12
LT - Lituania 11
NI - Nicaragua 11
PT - Portogallo 11
TN - Tunisia 10
PY - Paraguay 9
UY - Uruguay 9
AE - Emirati Arabi Uniti 8
GT - Guatemala 8
BG - Bulgaria 7
CZ - Repubblica Ceca 7
PE - Perù 7
TT - Trinidad e Tobago 7
AM - Armenia 6
AZ - Azerbaigian 6
DZ - Algeria 6
HN - Honduras 5
KZ - Kazakistan 5
LB - Libano 5
RS - Serbia 5
TW - Taiwan 5
AL - Albania 4
BO - Bolivia 4
DO - Repubblica Dominicana 4
EE - Estonia 4
GH - Ghana 4
PA - Panama 4
PS - Palestinian Territory 4
SV - El Salvador 4
TH - Thailandia 4
GR - Grecia 3
HU - Ungheria 3
IL - Israele 3
JO - Giordania 3
KG - Kirghizistan 3
LV - Lettonia 3
NG - Nigeria 3
OM - Oman 3
AO - Angola 2
BB - Barbados 2
BY - Bielorussia 2
LY - Libia 2
MD - Moldavia 2
MK - Macedonia 2
MM - Myanmar 2
PR - Porto Rico 2
QA - Qatar 2
SN - Senegal 2
XK - ???statistics.table.value.countryCode.XK??? 2
AD - Andorra 1
Totale 20.079
Salva come PNG Salva come JPEG
Città #
Ashburn 1.383
Fairfield 975
Singapore 952
San Jose 825
Chandler 487
Houston 454
Seattle 418
Woodbridge 405
Wilmington 352
Hong Kong 337
Cambridge 336
Palermo 308
Moscow 284
Ann Arbor 261
Council Bluffs 235
Zgierz 217
Helsinki 186
New York 180
Los Angeles 178
Rome 167
Beijing 166
Dallas 163
Chicago 142
Tokyo 140
Ho Chi Minh City 139
The Dalles 136
Santa Clara 118
Lauterbourg 110
Medford 102
Munich 102
Hefei 100
Hanoi 99
Boardman 95
Des Moines 88
Dublin 85
Altamura 77
Princeton 65
Buffalo 64
Frankfurt am Main 62
Lawrence 60
São Paulo 60
Milan 59
London 55
Ludwigshafen am Rhein 54
San Diego 53
Warsaw 48
Nanjing 47
Phoenix 45
Toronto 44
Denver 41
Orem 40
Seoul 38
Brooklyn 34
Montreal 34
Atlanta 32
Lappeenranta 32
Schiffdorf 32
Bremen 31
Dearborn 30
Nuremberg 30
Kitzingen 27
Stockholm 26
Panama City 25
Brussels 23
Johannesburg 22
Chennai 21
Mexico City 21
Redondo Beach 21
Amsterdam 19
Falls Church 19
Shanghai 19
Tashkent 19
Baghdad 18
Boston 18
Haiphong 18
Salt Lake City 18
Shenyang 18
Da Nang 17
Redwood City 17
Abidjan 16
Kumar 16
Manchester 16
Cairo 15
Nanchang 15
Tianjin 15
Washington 15
Guangzhou 14
Hebei 14
Springfield 14
Tampa 14
Volla 14
Belo Horizonte 13
Memphis 13
Newark 13
Philadelphia 13
Poplar 13
Curitiba 12
Erbil 12
Izmir 12
Jinan 12
Totale 12.569
Salva come PNG Salva come JPEG
Nome #
Clinical efficacy and safety of ezetimibe on major cardiovascular endpoints: Systematic review and meta-analysis of randomized controlled trials 502
Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial 376
Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus 371
PD-L1 expression as predictive biomarker in patients with NSCLC: A pooled analysis 358
Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials 349
Analysis of miRNA expression profile induced by short term starvation in breast cancer cells treated with doxorubicin 344
Dietary restriction: could it be considered as speed bump on tumor progression road? 339
"Back to a false normality": New intriguing mechanisms of resistance to PARP inhibitors 329
Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study 328
Analysis of Germline Gene Copy Number Variants of Patients with Sporadic Pancreatic Adenocarcinoma Reveals Specific Variations 322
Cardiotoxic Effects of Anti-VEGFR Tyrosine Kinase Inhibitors 313
Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer Patients Progressing after Docetaxel: A Prospective Single-Center Study 297
Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients 294
Metastatic site location influences the diagnostic accuracy of ctDNA EGFR- mutation testing in NSCLC patients: a pooled analysis 286
Triple negative breast cancer: Shedding light onto the role of pi3k/akt/mtor pathway 283
New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: Do all roads lead to RAS? 281
How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis 280
Monoclonal antibodies in gastrointestinal cancers 277
Nintedanib in NSCLC: Evidence to date and place in therapy 265
Farletuzumab for NSCLC: Exploiting a well-known metabolic pathway for a new therapeutic strategy 259
Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score 256
Non-Small Cell Lung Cancer Harboring Concurrent EGFR Genomic Alterations: A Systematic Review and Critical Appraisal of the Double Dilemma 247
Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis 244
Prognostic clinical factors in patients affected by non-small-cell lung cancer receiving Nivolumab 229
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC) 220
The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis 219
Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1 215
Monoclonal antibodies for the treatment of non-haematological tumours: Update of an expanding scenario 213
Can KRAS and BRAF mutations limit the benefit of liver resection in metastatic colorectal cancer patients? A systematic review and meta-analysis 213
2020 Reply to: Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials 212
Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab 211
Exploring the potential of multiomics liquid biopsy testing in the clinical setting of lung cancer 210
Real life triplet FIr/FOx chemotherapy in first-line metastatic pancreatic ductal adenocarcinoma patients: Recommended schedule for expected activity and safety and phase II study 205
Combined treatment with fulvestrant plus capecitabine in elderly advanced breast cancer (EABC): Three-year evaluation of efficacy and safety 201
Clinical parameters to guide decision-making in elderly metastatic colorectal CANCER patients treated with intensive cytotoxic and anti-angiogenic therapy 198
An update on the conquests and perspectives of cardio-oncology in the field of tumor angiogenesistargeting TKI-based therapy 197
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors 195
COVID-19 Infection in Cancer Patients: How Can Oncologists Deal With These Patients? 192
Anti-angiogenic drugs for second-line treatment of NSCLC patients: Just new pawns on the chessboard? 190
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) 189
KIT/PDGFRA Variant Allele Frequency as Prognostic Factor in Gastrointestinal Stromal Tumors (GISTs): Results From a Multi-Institutional Cohort Study 188
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? 187
Potential miRNAs involved in molecular pathways mediating the anticancer effects of short term starvation in breast cancer cells treated with doxorubicin 184
Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—A trial-level meta-analysis in PD-L1 selected subgroups 183
The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet? 177
The use of pegylated liposomal doxorubicin (PLD) in association with weekly paclitaxel as second line therapy in metastatic bladder carcinoma: final results 174
Liquid biopsy in colorectal carcinoma: the search for potential prognostic and predictive biomarkers 173
Dose-finding study of oxaliplatin associated to capecitabinebased preoperative chemoradiotherapy in locally advanced rectal cancer 173
Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement 173
Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay 172
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study 172
Impact of phospho-Akt expression on the clinical outcome and activity of gemcitabine and Akt inhibitors in pancreatic ductal adenocarcinoma 171
The emerging therapeutic landscape of alk inhibitors in non-small cell lung cancer 169
Molecular profiling of pancreatic neuroendocrine tumors (pNETS) and the clinical potential 168
Roles of Tumor-Educated Platelets (TEPs) in the biology of Non-Small Cell Lung Cancer (NSCLC): A systematic review. “Re-discovering the neglected biosources of the liquid biopsy family” 167
Effects of the number of removed lymph nodes on survival outcome in patients with sentinel node-negative breast cancer 166
Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab 162
Applications of Platelet Concentrates (PCs) in Regenerative Onco-Urology: A Systematic Review of Literature 161
BRCA functional domains associated with high risk of multiple primary tumors and domain-related sensitivity to olaparib: the Prometheus Study 158
The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis 158
On-treatment dynamics of circulating extracellular vesicles in the first-line setting of patients with advanced non-small cell lung cancer: the LEXOVE prospective study. 158
The significance of epidermal growth factor receptor uncommon mutations in non-small cell lung cancer: A systematic review and critical appraisal 157
Dose-finding study of intensive weekly alternating schedule of docetaxel, 5-fluorouracil, and oxaliplatin, FD/FOx regimen, in metastatic gastric cancer 156
Impact of BMI on Preoperative Axillary Ultrasound Assessment in Patients With Early Breast Cancer 156
Navigating the liquid biopsy Minimal Residual Disease (MRD) in non-small cell lung cancer: Making the invisible visible 155
Second medical opinion in oncological setting 155
The significance of tissue-agnostic biomarkers in solid tumors: the more the merrier? 152
Clinical utility of ctDNA by amplicon based next generation sequencing in first line non small cell lung cancer patients 151
Accuracy evaluation of orthodontic movements with aligners: a prospective observational study. 151
The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: An indirect comparison of randomized controlled trials 151
The use of same in chemotherapy-induced liver injury 149
The treatment of medication-related osteonecrosis of the jaw (Mronj): A systematic review with a pooled analysis of only surgery versus combined protocols 149
Current clinically validated applications of liquid biopsy 147
Ramucirumab and its use in gastric cancer treatment 147
Moving the target on the optimal adjuvant strategy for resected pancreatic cancers: A systematic review with meta-analysis 147
Molecular tumor board 146
Recent advances in liquid biopsy for precision oncology: emerging biomarkers and clinical applications in lung cancer 146
Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses 142
How do skeletal morbidity rate and special toxicities affect 12-week versus 4-week schedule zoledronic acid efficacy? A systematic review and a meta-analysis of randomized trials 139
Anthracycline-related cardiotoxicity in patients with breast cancer harboring mutational signature of homologous recombination deficiency (HRD) 138
A narrative review on the implementation of liquid biopsy as a diagnostic tool in thoracic tumors during the COVID-19 pandemic 136
Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis 135
Scientific Communication and oncology – "The bridge between knowledge and patients" 134
Polθ: emerging synthetic lethal partner in homologous recombination-deficient tumors 132
Artificial Intelligence Predictive Models of Response to Cytotoxic Chemotherapy Alone or Combined to Targeted Therapy for Metastatic Colorectal Cancer Patients: A Systematic Review and Meta-Analysis 130
The intersection of homologous recombination (HR) and mismatch repair (MMR) pathways in DNA repair-defective tumors 129
Extracellular Vesicles in Lung Cancer: Implementation in Diagnosis and Therapeutic Perspectives 126
Indications for locoregional tumor therapies: CRC liver metastases 126
Potential Applications of PRP-Enhanced Polybutylene Succinate Graft as Vascular Access for Chemotherapy in Oncological Patients: A Systematic Review 125
Anti-vibration Knob for the Motorcycle, Customizable on the Basis of the Driver’s Ergonomics 125
Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis 125
The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials 122
The challenge of the Molecular Tumor Board empowerment in clinical oncology practice: A Position Paper on behalf of the AIOM- SIAPEC/IAP-SIBioC-SIC-SIF-SIGU-SIRM Italian Scientific Societies 121
The role of bone modifying agents for secondary osteoporosis prevention and pain control in post-menopausal osteopenic breast cancer patients undergoing adjuvant aromatase inhibitors 118
Liquid biopsy and immunotherapy: is all that glitter gold? 118
Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis 116
Early detection screening: myth or reality? 116
The prognostic role of KRAS and BRAF in patients undergoing surgical resection of colorectal cancer liver metastasis: a systematic review and meta-analysis 116
Editorial: The Effect of the COVID-19 Pandemic on Cancer Patients and Healthcare 111
Next generation diagnostic algorithm in non-small cell lung cancer predictive molecular pathology: The KWAY Italian multicenter cost evaluation study 109
Totale 19.607
Salva come PNG Salva come JPEG
Categoria #
all - tutte 72.366
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 72.366
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022766 0 0 0 39 62 60 59 65 99 139 89 154
2022/20231.404 145 274 25 180 119 216 84 123 113 20 77 28
2023/2024859 28 96 74 71 59 130 108 80 30 31 14 138
2024/20252.751 73 181 173 186 122 203 338 239 151 317 340 428
2025/20268.339 682 302 574 780 930 1.186 1.174 895 620 499 321 376
2026/20272.165 602 453 802 308 0 0 0 0 0 0 0 0
Totale 20.825